denagliptin
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Apr 1, 2005 (NCT00111800)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dipeptidyl peptidase IVINHIBITOR
DPP4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
N#C[C@@H]1C[C@H](F)CN1C(=O)[C@@H](N)C(c1ccc(F)cc1)c1ccc(F)cc1- Mol. weight
- 373.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2110666 ↗
Also known as
- 4-fluoro-1-(4-fluoro-(4-fluorophenyl)phenylalanyl)-2-pyrrolidinecarbonitrile
- denagliptin
- denagliptin
- denagliptin
- gw0823093
- gw823093
- gw823093
- gw823093c
- gw823093c
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00387972 | Phase 2/Phase 3 (Phase 3) | May 1, 2006 | GlaxoSmithKline |
| NCT00370942 | Phase 2 | Apr 1, 2006 | GlaxoSmithKline |
| NCT00372957 | Phase 2 | Mar 1, 2006 | GlaxoSmithKline |
| NCT00111800 | Phase 2 | Apr 1, 2005 | GlaxoSmithKline |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 4 | 4 | 2 | 2005 |
1 organizations
Page 1 / 1